Trial · NCT07905352
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
NCT07905352, Phase 2, Not yet recruiting, Vigonvita Life Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease. Trials, record NCT07905352. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905352
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
- NCT number
- NCT07905352
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Vigonvita Life Sciences
- Conditions
- Alzheimer Disease
- Interventions
- Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg, Placebo Tablets
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) | 52 Weeks | Change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) total score at Week 26 and Week 52. Possible scores range from 0 to 18; higher scores represent greater dementia impairment (worse outcome). |
| Secondary | Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13) | 52 Weeks | Change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13) score at Week 26 and Week 52. Possible scores range from 0 to 85; higher scores represent worse cognitive function (worse outcome). |
| Secondary | Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) | 52 Weeks | Change from baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score at Week 26 and Week 52. Possible scores range from 0 to 78; higher scores represent better daily function (better outcome). |
| Secondary | 15-item Geriatric Depression Scale (GDS-15) | 52 Weeks | Change from baseline in the 15-item Geriatric Depression Scale (GDS-15) score at Week 26 and Week 52. Possible scores range from 0 to 15; higher scores represent more severe depressive symptoms (worse outcome). |
| Secondary | Mini-Mental State Examination (MMSE) | 52 Weeks | Change from baseline in the Mini-Mental State Examination (MMSE) score at Week 26 and Week 52. Possible scores range from 0 to 30; higher scores represent better global cognitive function (better outcome). |
| Secondary | Plasma p-tau181 | 52 Weeks | Change from baseline in plasma p-tau181 concentration at Week 26 and Week 52. |
| Secondary | Plasma p-tau217 | 52 Weeks | Change from baseline in plasma p-tau217 concentration at Week 26 and Week 52. |
| Secondary | Plasma p-tau231 | 52 Weeks | Change from baseline in plasma p-tau231 concentration at Week 26 and Week 52. |
| Secondary | Plasma Aβ42 | 52 Weeks. | Change from baseline in plasma Aβ42 concentration at Week 26 and Week 52. |
| Secondary | Plasma Aβ40 | 52 Weeks | Change from baseline in plasma Aβ40 concentration at Week 26 and Week 52. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905352
GET https://conductscience.org/api/trials/v1/NCT07905352/registered